Quince Therapeutics (QNCX) Net Income towards Common Stockholders (2018 - 2026)

Quince Therapeutics' Net Income towards Common Stockholders history runs 9 years deep, the most recent figure standing at $32.8 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 318.19% year-over-year to $32.8 million; the TTM figure through Mar 2026 stood at -$16.0 million (up 73.68% YoY), while the FY2025 annual figure was -$63.8 million, down 12.28% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at $32.8 million, up from -$19.3 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $32.8 million in Q1 2026, with the low at -$27.7 million in Q2 2024.
• The 5-year median for Net Income towards Common Stockholders is -$12.3 million (2023), against an average of -$10.1 million.
• The sharpest annual moves came in 2024 and 2026: Net Income towards Common Stockholders tumbled 467.52% in 2024, then surged 318.19% in 2026.
• Quince Therapeutics' Net Income towards Common Stockholders stood at -$5.5 million in 2022, then slumped by 60.72% to -$8.9 million in 2023, then tumbled by 40.07% to -$12.5 million in 2024, then sank by 54.78% to -$19.3 million in 2025, then jumped by 270.07% to $32.8 million in 2026.
• Business Quant data shows QNCX's Net Income towards Common Stockholders at $32.8 million in Q1 2026, -$19.3 million in Q4 2025, and -$13.4 million in Q3 2025.